Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

Italian authorities released the director of a notorious detention camp who had been arrested in Turin on an ICC war crimes warrant. Italian police were acting on an arrest warrant from the ...

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

According to a press release from Denali Therapeutics Inc., the small molecule DNL343 was examined in the Healey ALS Platform study, whose primary endpoint was change in disease severity measured ...

Denali Therapeutics recently disclosed the outcomes of its HEALEY trial, which evaluated DNL343, an agonist of eIF2B intended for the treatment of amyotrophic lateral sclerosis (ALS). The trial failed ...

The revision followed the announcement that Denali's DNL343, an eIF2B inhibitor, did not achieve the primary or key secondary endpoints in the phase 2/3 HEALEY trial for amyotrophic lateral sclerosis ...